🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

BREAKING: In a stunning reversal, #Biogen announced that it will take its anti-amyloid drug #aducanumab to the U.S. FDA after a new, larger analysis showed positive results in patients with early #Alzheimersdisease neurologylive.com/clinical-focus…

BREAKING: #FDA approves diroximel fumarate for the treatment of relapsing forms of #multiplesclerosis, including CIS. Read more: neurologylive.com/clinical-focus…

President Donald Trump has announced that #StephenHahn will be his nomination to lead the U.S. FDA. Read more: neurologylive.com/clinical-focus…

BREAKING: #FDA approves cenobamate for the treatment of partial-onset seizures in adults. neurologylive.com/clinical-focus…

#BREAKING: The U.S. FDA has approved #riluzole oral film for the treatment of #ALS. Read more: neurologylive.com/clinical-focus…

Breaking: Top-line results from phase 3 #HARMONY trial of #pimavanserin in #dementia related psychosis show significant reduction in relapse risk vs placebo. Jeffrey Cummings of Cleveland Clinic MD spoke with us about the results presented at #CTAD neurologylive.com/clinical-focus…

#Breaking: Biogen's #aducanumab data readout at #CTAD19 shows that a high-dose of the drug reduces clinical decline. neurologylive.com/clinical-focus…

#BreakingNews from the FDA tonight as the agency approves #golodirsen for the treatment of #duchenne muscular dystrophy amenable to exon 53 skipping. Read more: neurologylive.com/clinical-focus…

BREAKING NEWS: The FDA has approved Eisai's #lemborexant for the treatment of #insomnia in adults. Read more: neurologylive.com/clinical-focus…

BREAKING NEWS: #Ubrogepant is FDA-approved for the treatment of acute #migraine in adults. More details here: neurologylive.com/clinical-focus…

BREAKING: The U.S. FDA has approved intranasal #diazepam (Valtoco) for the treatment of acute, intermittent, stereotypic episodes of frequent #seizure activity, otherwise known as seizure clusters or acute repetitive seizures. NEURELIS JAIME neurologylive.com/clinical-focus…

Sure, #aducanumab, if successful, will be good for Biogen and #Alzheimers disease, but what does its success mean for the drug development pipeline? ProMIS Neurosciences CMO James Kupiec, MD discusses the impact on drug innovation. Read his editorial here: neurologylive.com/clinical-focus…

#BREAKING: The FDA has approved eptinezumab-jjmr (Vyepti; Lundbeck) for the preventive treatment of migraine in adult patients. It will become available for prescription in April 2020, with a recommended dose of 100 mg, quarterly. neurologylive.com/clinical-focus…

#BREAKING: The FDA has accepted the sBLA for Novartis' #ofatumumab for the treatment of relapsing forms of #MS in adults. Read more: neurologylive.com/clinical-focus…

HAPPENING NOW: Webinar on outpatient #teleneurology updates in age of #COVID19 Click here for access to this free webinar happening now! bit.ly/3d4Dy3r

#BREAKING: The FDA has approved #ozanimod for the treatment of relapsing forms of #multiplesclerosis. Read more about the oral S1P modulator right here: neurologylive.com/clinical-focus…

Join us this Thursday at 6PM ET for a live webinar: Impact of #COVID19 on #MultipleSclerosis Management A timely and informative presentation by Mitzi Williams, MD @NerdyNeuroMD in partnership with Women Neurologists Group REGISTER NOW: bit.ly/2QXUDTe #MSCOVID19

#BREAKING: The U.S. FDA has approved #Neurocrine Biosciences' #opicapone for the adjunctive treatment of OFF episodes in #Parkinsons disease. Read more: neurologylive.com/clinical-focus…

Today's the day! Join us and Beth Morton at 8PM EST for our discussion on #migraine in honor of #MHAM!

#BREAKING: The U.S. FDA has set a PDUFA date for #Alzheimers disease tx #aducanumab for March 7, 2021. READ MORE: neurologylive.com/clinical-focus…